Nivolumab maintenance (post-induction nivo+ipi, advanced melanoma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-NIVOLUMAB |
|---|
| ID | REG-NIVO-MAINTENANCE-MELANOMA |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-CHECKMATE-067-LARKIN-2019 SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Notes
CheckMate-067 (Larkin 2019/2022, NEJM): nivolumab + ipilimumab induction (4 cycles) followed by nivolumab maintenance every 2 weeks (240 mg) or every 4 weeks (480 mg flat-dose) — 6.5-year mOS 49% vs 22% (chemo). Maintenance phase critical for long-term benefit. TSH/free T4 q6-8 weeks; AM cortisol if symptomatic; LFTs q2-4 weeks for first 6 months, then q4 weeks. irAE management per ASCO/ESMO guidelines.
Used By
Indication
IND-MELANOMA-NIVO-MAINT- IND-MELANOMA-NIVO-MAINT